In response to the COVID-19 pandemic, Research and the Diagnostic communities have placed demands on the antibody production market that are unprecedented in scale. This spike in demand combined with the global restriction of capacity has emphasized the importance of relying on antibody development and manufacturing partners that employ scalable and robust antibody production and purification capabilities supported by quality management systems that are appropriate for the prospective antibodies’ fields of use.
In this presentation, the speakers will outline MilliporeSigma’s contract antibody development, manufacturing, purification, and cell banking capabilities and capacity highlighting investments made to support large-scale recombinant and traditional hybridoma-based antibody production in an industry-leading manufacturing environment.
In this webinar, you will learn about:
Michael Moehlenbrock, Ph.D.
Business Development Manager - Diagnostic Immunoassays
Michael Moehlenbrock Ph.D. is currently a Business Development Manager and specialist in diagnostic immunoassays for MilliporeSigma. Before this role, Michael held several roles in product management including head of product management for MilliporeSigma Research Antibodies portfolio. Michael has his Ph.D., and Bachelor’s degree in Chemistry from St. Louis University where his interdisciplinary research areas of focus included microfluidic analytical chemistry, enzymatic biosensors and biofuels cells, enzymology, and metabolic substrate channeling, and materials chemistry
Sinead McManus is currently an R&D Manager in the Antibody Discovery group at MilliporeSigma based in Livingston, Scotland, UK. Sinead earned her B.Sc. in Biotechnology from Dublin City University, Ireland. Sinead joined MilliporeSigma in 2006 and has held various roles in the company. Sinead has introduced many different single-use manufacturing processes to the Livingston site which are now routinely used by ISCO (Integrated Supply Chain Operations) for antibody production. Sinead oversees the entire process from developing antibodies, scaling and optimizing fermentation conditions, developing purification processes, and transferring the antibodies to production for antibody manufacture.
Jennifer McGrath is currently an R&D Scientist in the Antibody Discovery group at MilliporeSigma based in Livingston, Scotland UK. Jennifer earned her B.Sc. in Genetics at The University of Glasgow. Jennifer joined MilliporeSigma in 2013 as a manufacturing scientist focusing primarily on upstream processing and monoclonal antibody production through tissue culture and fermentation. As an R&D Scientist, she is involved in developing antibodies, scaling, and optimizing new products, and improving current processes. Jennifer provides technical support to the Livingston facility developing new products and processes to support the supply of diagnostic products.
To continue reading please sign in or create an account.Don't Have An Account?